Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis

Margreet Kloppenburg, Charles Peterfy, Ida K Haugen, Féline Kroon, Su Chen, Li Wang, Wei Liu, Gwen Levy, Roy M Fleischmann, Francis Berenbaum, Désirée van der Heijde, Prashant Bansal, Ruth Wittoek, Sheng Feng, Yuni Fang, Mary Saltarelli, Jeroen K Medema, Marc C Levesque, Margreet Kloppenburg, Charles Peterfy, Ida K Haugen, Féline Kroon, Su Chen, Li Wang, Wei Liu, Gwen Levy, Roy M Fleischmann, Francis Berenbaum, Désirée van der Heijde, Prashant Bansal, Ruth Wittoek, Sheng Feng, Yuni Fang, Mary Saltarelli, Jeroen K Medema, Marc C Levesque

Abstract

Objective: To assess the efficacy, safety, pharmacokinetics and pharmacodynamics of the anti-interleukin (IL)-1α/β dual variable domain immunoglobulin lutikizumab (ABT-981) in erosive hand osteoarthritis (HOA).

Methods: Patients with ≥1 erosive and ≥3 tender and/or swollen hand joints were randomised to placebo or lutikizumab 200 mg subcutaneously every 2 weeks for 24 weeks. The primary endpoint was change in Australian/Canadian Osteoarthritis Hand Index (AUSCAN) pain subdomain score from baseline to 16 weeks. At baseline and week 26, subjects had bilateral hand radiographs and MRI of the hand with the greatest number of baseline tender and/or swollen joints. Continuous endpoints were assessed using analysis of covariance models, with treatment and country as main factors and baseline measurements as covariates.

Results: Of 132 randomised subjects, 1 received no study drug and 110 completed the study (placebo, 61/67 (91%); lutikizumab, 49/64 (77%)). AUSCAN pain was not different among subjects treated with lutikizumab versus placebo at week 16 (least squares mean difference, 1.5 (95% CI -1.9 to 5.0)). Other clinical and imaging endpoints were not different between lutikizumab and placebo. Lutikizumab significantly decreased serum high-sensitivity C reactive protein levels, IL-1α and IL-1β levels, and blood neutrophils. Lutikizumab pharmacokinetics were consistent with phase I studies and not affected by antidrug antibodies. Injection site reactions and neutropaenia were more common in the lutikizumab group; discontinuations because of adverse events occurred more frequently with lutikizumab (4/64) versus placebo (1/67).

Conclusion: Despite adequate blockade of IL-1, lutikizumab did not improve pain or imaging outcomes in erosive HOA compared with placebo.

Trial registration: ClinicalTrials.gov NCT02384538.

Keywords: DMOADs (biologic); hand osteoarthritis; inflammation; interleukin-1.

Conflict of interest statement

Competing interests: AbbVie contributed to the design of the study and was involved in the collection, analysis and interpretation of the data, and in the writing, review and approval of the publication. MK has received grant/research support from Pfizer and been a consultant for AbbVie, GlaxoSmithKline, Merck and Levicept. CP is an employee of Spire Sciences, and is on the speakers' bureau for Amgen and Bristol-Myers Squibb. IKH has been a consultant for AbbVie. FK has no conflicts of interest to declare. RMF has received grant/research support from and has been a consultant for AbbVie. FB has been a consultant for AbbVie, Pfizer and Regeneron. DvdH has been a consultant for AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Boehringer-Ingelheim, Celgene, Daiichi, Eli Lilly, Galapagos, Gilead, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi and UCB; she is Director of Imaging Rheumatology. PB is a former employee of PAREXEL, which performed work for this study under contract to AbbVie. RW has been a consultant for AbbVie. SC, LW, WL, GL, YF, MS, JKM and MCL are employees of AbbVie and may own AbbVie stock and/or stock options. SF is a former employee of AbbVie and may own AbbVie stock and/or stock options.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
LS mean change from baseline in AUSCAN pain over time (A) and LS mean change from baseline in AUSCAN function over time (B). Last observation carried forward imputation was used for analysis when values were missing. All comparisons of lutikizumab versus placebo were not significant using an analysis of covariance adjusted for treatment group and country as factors, and including baseline value as a covariate. AUSCAN, Australian/Canadian Osteoarthritis Hand Index; LS, least squares.
Figure 2
Figure 2
Assessment of radiographic endpoints (A) and MRI endpoints using the Outcome Measures in Rheumatology Clinical Trials/Hand Osteoarthritis MRI Scoring system (HOAMRIS) (B). *Defined by Verbruggen et al as joints that entered the erosive, erosive with remodelling or remodelling phase but were normal, stationary or only starting to lose joint space at baseline. P values for lutikizumab versus placebo are from an analysis of covariance model adjusted for age group and Kellgren-Lawrence score as factors, and including baseline value as a covariate. BML, bone marrow lesions; JSN, joint space narrowing; LS, least squares; OARSI, Osteoarthritis Research Society International.
Figure 3
Figure 3
Mean hsCRP levels (A), neutrophil counts (B) and C1M levels (C) over time. *P

References

    1. Dahaghin S, Bierma-Zeinstra SM, Ginai AZ, et al. . Prevalence and pattern of radiographic hand osteoarthritis and association with pain and disability (the Rotterdam study). Ann Rheum Dis 2005;64:682–7. 10.1136/ard.2004.023564
    1. Haugen IK, Englund M, Aliabadi P, et al. . Prevalence, incidence and progression of hand osteoarthritis in the general population: the Framingham Osteoarthritis Study. Ann Rheum Dis 2011;70:1581–6. 10.1136/ard.2011.150078
    1. Zhang W, Doherty M, Leeb BF, et al. . EULAR evidence-based recommendations for the diagnosis of hand osteoarthritis: report of a task force of ESCISIT. Ann Rheum Dis 2009;68:8–17. 10.1136/ard.2007.084772
    1. Haugen IK, Mathiessen A, Slatkowsky-Christensen B, et al. . Synovitis and radiographic progression in non-erosive and erosive hand osteoarthritis: is erosive hand osteoarthritis a separate inflammatory phenotype? Osteoarthritis Cartilage 2016;24:647–54. 10.1016/j.joca.2015.11.014
    1. Bijsterbosch J, Watt I, Meulenbelt I, et al. . Clinical burden of erosive hand osteoarthritis and its relationship to nodes. Ann Rheum Dis 2010;69:1784–8. 10.1136/ard.2009.125435
    1. Wittoek R, Cruyssen BV, Verbruggen G. Predictors of functional impairment and pain in erosive osteoarthritis of the interphalangeal joints: comparison with controlled inflammatory arthritis. Arthritis Rheum 2012;64:1430–6. 10.1002/art.33502
    1. Zhang Y, Niu J, Kelly-Hayes M, et al. . Prevalence of symptomatic hand osteoarthritis and its impact on functional status among the elderly: the Framingham Study. Am J Epidemiol 2002;156:1021–7. 10.1093/aje/kwf141
    1. Hochberg MC, Altman RD, April KT, et al. . American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012;64:465–74. 10.1002/acr.21596
    1. Kloppenburg M. Hand osteoarthritis-nonpharmacological and pharmacological treatments. Nat Rev Rheumatol 2014;10:242–51. 10.1038/nrrheum.2013.214
    1. Verbruggen G, Wittoek R, Vander Cruyssen B, et al. . Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification. Ann Rheum Dis 2012;71:891–8. 10.1136/ard.2011.149849
    1. Kloppenburg M, Ramonda R, Kwok W-Y, et al. . OP0095 randomized, placebo-controlled trial to evaluate clinical efficacy and structure modifying properties of subcutaneous etanercept (ETN) in patients with erosive inflammatory hand osteoarthritis (OA). Ann Rheum Dis 2016;75(Suppl 2):90.3–1. 10.1136/annrheumdis-2016-eular.3663
    1. Kingsbury SR, Tharmanathan P, Keding A, et al. . Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis: a randomized trial. Ann Intern Med 2018;168:385–95. 10.7326/M17-1430
    1. Kloppenburg M, Kroon FP, Blanco FJ, et al. . 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis 2019;78:16–24. 10.1136/annrheumdis-2018-213826
    1. de Oliveira CMB, Sakata RK, Issy AM, et al. . Cytokines and Pain. Braz J Anesthesiol 2011;61:255–65. 10.1016/S0034-7094(11)70029-0
    1. Kapoor M, Martel-Pelletier J, Lajeunesse D, et al. . Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 2011;7:33–42. 10.1038/nrrheum.2010.196
    1. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008;118:3537–45. 10.1172/JCI36389
    1. Dayer JM. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology 2003;42(Suppl 2):3ii–10. 10.1093/rheumatology/keg326
    1. Lorenzo J, Horowitz M, Choi Y. Osteoimmunology: interactions of the bone and immune system. Endocr Rev 2008;29:403–40. 10.1210/er.2007-0038
    1. Jules J, Zhang P, Ashley JW, et al. . Molecular basis of requirement of receptor activator of nuclear factor κB signaling for interleukin 1-mediated osteoclastogenesis. J Biol Chem 2012;287:15728–38. 10.1074/jbc.M111.296228
    1. Schett G, Dayer JM, Manger B. Interleukin-1 function and role in rheumatic disease. Nat Rev Rheumatol 2016;12:14–24. 10.1038/nrrheum.2016.166
    1. Zhang P, Zhong ZH, Yu HT, et al. . Exogenous expression of IL-1Ra and TGF-β1 promotes in vivo repair in experimental rabbit osteoarthritis. Scand J Rheumatol 2015;44:404–11. 10.3109/03009742.2015.1009942
    1. Chevalier X, Goupille P, Beaulieu AD, et al. . Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2009;61:344–52. 10.1002/art.24096
    1. Cohen SB, Proudman S, Kivitz AJ, et al. . A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee. Arthritis Res Ther 2011;13:R125 10.1186/ar3430
    1. Kerkhof HJ, Doherty M, Arden NK, et al. . Large-scale meta-analysis of interleukin-1 beta and interleukin-1 receptor antagonist polymorphisms on risk of radiographic hip and knee osteoarthritis and severity of knee osteoarthritis. Osteoarthritis Cartilage 2011;19:265–71. 10.1016/j.joca.2010.12.003
    1. Stern AG, de Carvalho MR, Buck GA, et al. . Association of erosive hand osteoarthritis with a single nucleotide polymorphism on the gene encoding interleukin-1 beta. Osteoarthritis Cartilage 2003;11:394–402. 10.1016/S1063-4584(03)00054-2
    1. Bacconnier L, Jorgensen C, Fabre S. Erosive osteoarthritis of the hand: clinical experience with anakinra. Ann Rheum Dis 2009;68:1078–9. 10.1136/ard.2008.094284
    1. Lacy SE, Wu C, Ambrosi DJ, et al. . Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig) molecule that specifically and potently neutralizes both IL-1α and IL-1β. MAbs 2015;7:605–19. 10.1080/19420862.2015.1026501
    1. Kamath RV, Hart M, Conlon D, et al. . Simultaneous targeting of IL-1A and IL-1B by a dual-variable-domain immunoglobulin (DVD-IG) prevents cartilage degradation in preclinical models of osteoarthritis. Osteoarthritis Cartilage 2011;19:S64 10.1016/S1063-4584(11)60153-2
    1. Kamath RV, Simler G, Zhou C, et al. . Blockade of both IL-1A and IL-1B by a combination of monoclonal antibodies prevents the development and reverses established pain in a preclinical model of osteoarthritis. Osteoarthritis Cartilage 2012;20:S62 10.1016/j.joca.2012.02.031
    1. Wang SX, Abramson SB, Attur M, et al. . Safety, tolerability, and pharmacodynamics of an anti-interleukin-1α/β dual variable domain immunoglobulin in patients with osteoarthritis of the knee: a randomized phase 1 study. Osteoarthritis Cartilage 2017;25:1952–61. 10.1016/j.joca.2017.09.007
    1. Maheu E, Altman RD, Bloch DA, et al. . Design and conduct of clinical trials in patients with osteoarthritis of the hand: recommendations from a task force of the Osteoarthritis Research Society International. Osteoarthritis Cartilage 2006;14:303–22. 10.1016/j.joca.2006.02.010
    1. Altman R, Alarcón G, Appelrouth D, et al. . The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum 1990;33:1601–10. 10.1002/art.1780331101
    1. Verbruggen G, Wittoek R, Vander Cruyssen B, et al. . Morbid anatomy of 'erosive osteoarthritis' of the interphalangeal finger joints: an optimised scoring system to monitor disease progression in affected joints. Ann Rheum Dis 2010;69:862–7. 10.1136/ard.2009.112714
    1. Bellamy N, Campbell J, Haraoui B, et al. . Dimensionality and clinical importance of pain and disability in hand osteoarthritis: Development of the Australian/Canadian (AUSCAN) Osteoarthritis Hand Index. Osteoarthritis Cartilage 2002;10:855–62. 10.1053/joca.2002.0837
    1. Verbruggen G, Veys EM. Numerical scoring systems for the anatomic evolution of osteoarthritis of the finger joints. Arthritis Rheum 1996;39:308–20. 10.1002/art.1780390221
    1. Altman RD, Gold GE. Atlas of individual radiographic features in osteoarthritis, revised. Osteoarthritis Cartilage 2007;15(suppl A):A1–A56. 10.1016/j.joca.2006.11.009
    1. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957;16:494–502. 10.1136/ard.16.4.494
    1. Haugen IK, Bøyesen P. Imaging modalities in hand osteoarthritis--and perspectives of conventional radiography, magnetic resonance imaging, and ultrasonography. Arthritis Res Ther 2011;13:248 10.1186/ar3509
    1. Haugen IK, Østergaard M, Eshed I, et al. . Iterative development and reliability of the OMERACT hand osteoarthritis MRI scoring system. J Rheumatol 2014;41:386–91. 10.3899/jrheum.131086
    1. Bellamy N, Campbell J, Haraoui B, et al. . Clinimetric properties of the AUSCAN Osteoarthritis Hand Index: an evaluation of reliability, validity and responsiveness. Osteoarthritis Cartilage 2002;10:863–9. 10.1053/joca.2002.0838
    1. Kvien TK, Fjeld E, Slatkowsky-Christensen B, et al. . Efficacy and safety of a novel synergistic drug candidate, CRx-102, in hand osteoarthritis. Ann Rheum Dis 2008;67:942–8. 10.1136/ard.2007.074401
    1. Altman RD, Dreiser RL, Fisher CL, et al. . Diclofenac sodium gel in patients with primary hand osteoarthritis: a randomized, double-blind, placebo-controlled trial. J Rheumatol 2009;36:1991–9. 10.3899/jrheum.081316
    1. Grifka JK, Zacher J, Brown JP, et al. . Efficacy and tolerability of lumiracoxib versus placebo in patients with osteoarthritis of the hand. Clin Exp Rheumatol 2004;22:589–96.
    1. Fleischmann RM, Bliddal H, Blanco FJ, et al. . Safety and efficacy of ABT-981, an anti–interleukin-1α/β dual variable domain (DVD) immunoglobulin, in subjects with knee osteoarthritis: results from the randomized, double-blind, placebo-controlled, parallel-group phase 2 trial. Arthritis Rheumatol 2017;69:1196.
    1. van Dalen SC, Blom AB, Slöetjes AW, et al. . Interleukin-1 is not involved in synovial inflammation and cartilage destruction in collagenase-induced osteoarthritis. Osteoarthritis Cartilage 2017;25:385–96. 10.1016/j.joca.2016.09.009
    1. Howard C, Noe A, Skerjanec A, et al. . Safety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies. Cardiovasc Diabetol 2014;13:94 10.1186/1475-2840-13-94
    1. Sundy JS, Schumacher HR, Kivitz A, et al. . Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study. J Rheumatol 2014;41:1703–11. 10.3899/jrheum.131226
    1. KINERET® (anakinra) Full Prescribing Information. Stockholm, Sweden: Swedish Orphan Biovitrum AB, 2016.
    1. ARCALYST® (rilonacept) Full Prescribing Information. Tarrytown, NY: Regeneron Pharmaceuticals, Inc., 2016.
    1. Chevalier X, Ravaud P, Maheu E, et al. . Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial. Ann Rheum Dis 2015;74:1697–705. 10.1136/annrheumdis-2014-205348
    1. Aitken D, Pan F, Laslett L, et al. . A randomised double-blind placebo-controlled crossover trial of humira (adalimumab) for erosive hand osteoarthritis: the humor trial. Osteoarthritis Cartilage 2017;25:S9 10.1016/j.joca.2017.02.032
    1. Fioravanti A, Fabbroni M, Cerase A, et al. . Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: a pilot study. Rheumatol Int 2009;29:961–5. 10.1007/s00296-009-0872-0
    1. Magnano MD, Chakravarty EF, Broudy C, et al. . A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands. J Rheumatol 2007;34:1323–7.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere